Submit Manuscript

Journal of Biological Sciences

Year: 2005 | Volume: 5 | Issue: 1 | Page No.: 66-69
Facebook Twitter Digg Reddit Linkedin StumbleUpon E-mail
Research Article

Role of VHL in Mammalian Oxygen Sensing

Ryan C. Russell and Michael Ohh

ABSTRACT

The Von Hippel Lindau (VHL) tumour suppressor protein is a component of a multimeric protein complex VEC, which is an E3 ubiquitin ligase that specifically ubiquitylates the subunit of Hypoxia Inducible Factor (HIF) for subsequent destruction by the 26S proteasome. This establishes VHL as a critical regulator of oxygen-mediated gene expression and a central player in mammalian oxygen sensing. This review will highlight the recent advancements in our understanding of the molecular mechanisms governing the activity of the VEC complex.
PDF References Citation

Search

REFERENCES

  1. Ohh, M. and W.G. Jr. Kaelin, 2003. VHL and kidney cancer. Methods Mol. Biol., 222: 167-183.
  2. Seizinger, B.R., G.A. Rouleau, L.J. Ozelius, A.H. Lane and G.E. Farmer et al., 1988. Von-hippel lindau disease maps to the region of chromosome 3 associated with renal cell carcinoma. Nature, 332: 268-269.
  3. Latif, F., K. Tory, J. Gnarra, M. Yao and F.M. Duh et al., 1993. Identification of the Von Hippel Lindau disease tumor suppressor gene. Science, 260: 1317-1320.
  4. Iliopoulos, O., M. Ohh and W. Kaelin, 1998. pVHL19 is a biologically active product of the Von Hippel Lindau gene arising from internal translation initiation. Proc. Natl. Acad. Sci. USA, 95: 11661-11666.
  5. Schoenfeld, A., E.J. Davidowitz and R.D. Burk, 1998. A second major native Von Hippel Lindau gene product, initiated from an internal translation start site, functions as a tumor suppressor. Proc. Natl. Acad. Sci. USA., 95: 8817-8822.
  6. Lee, S., D.Y.T. Chen, J.S. Humphrey, J.R. Gnarra, W.M. Linehan and R.D. Klausner, 1996. Nuclear/cytoplasmic localization of the Von Hippel Lindau tumor suppressor gene product is determined by cell density. Proc. Natl. Acad. Sci. USA., 93: 1770-1775.
  7. Mekhail, K., L. Gunaratnam, M.E. Bonicalzi and S. Lee, 2004. HIF activation by pH-dependent nucleolar sequestration of VHL. Nature Cell Biol., 6: 642-647.
  8. Clifford, S.C., M.E. Cockman, A.C. Smallwood, D.R. Mole and E.R. Woodward et al., 2001. Contrasting effects on HIF-1α regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in Von Hippel Lindau disease. Hum. Mol. Genet., 10: 1029-1038.
  9. Hoffman, M.A., M. Ohh, H. Yang, J.M. Klco, M. Ivan and W.G. Jr. Kaelin, 2001. Von Hippel Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF. Hum. Mol. Genet., 10: 1019-1027.
  10. Ohh, M., R.L. Yauch, K.M. Lonergan, J.M. Whaley and A.O. Stemmer-Rachamimov et al., 1998. The Von Hippel Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix. Mol. Cell, 1: 959-968.
  11. Stebbins, C.E., W.G. Kaelin and N.P. Pavletich, 1999. Structure of the VHL-ElonginC-elonginB complex: Implications for VHL tumor suppressor function. Science, 284: 455-461.
  12. Maynard, M.A. and M. Ohh, 2004. Von Hippel Lindau tumor suppressor protein and hypoxia inducible factor in kidney cancer. Am. J. Nephrol., 24: 1-13.
  13. Maxwell, P., M. Weisner, G.W. Chang, S. Clifford and E. Vaux et al., 1999. The Von Hippel Lindau gene product is necessary for oxgyen-dependent proteolysis of hypoxia inducible factor α subunits. Nature, 399: 271-275.
  14. Masson, N., C. Willam, P.H. Maxwell, C.W. Pugh, and P.J. Ratcliffe, 2001. Independent function of two destruction domains in Hypoxia Inducible Factor-alpha chains activated by prolyl hydroxylation. EMBO J., 20: 5197-5206.
  15. Ivan, M., K. Kondo, H. Yang, W. Kim and J. Valiando et al., 2001. HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: Implications for O2 sensing. Science, 292: 464-468.
    CrossRef
  16. Jaakkola, P., D.R. Mole, Y.M. Tian, M.I. Wilson and J. Gielbert et al., 2001. Targeting of HIF-alpha to the Von Hippel Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science, 292: 468-472.
  17. Epstein, A.C., J.M. Gleadle, L.A. McNeill, K.S. Hewitson and J. O'Rourke et al., 2001. Elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell, 107: 43-54.
    PubMed
  18. D'Angelo, G., E. Duplan, N. Boyer, P. Vigne and C. Frelin, 2003. Hypoxia up-regulates prolyl hydroxylase activity: A feedback mechanism that limits HIF-1 responses during reoxygenation. J. Biol. Chem., 278: 38183-38187.
  19. Ohh, M., W.Y. Kim, J.J. Moslehi, Y. Chen, V. Chau, M.A. Read and W.G. Kaelin, 2002. An intact NEDD8 pathway is required for Cullin-dependent ubiquitylation in mammalian cells. EMBO Rep., 3: 177-182.
  20. Maynard, M.A., H. Qi, J. Chung, E.H. Lee and Y. Kondo et al., 2003. Multiple splice variants of the human HIF-3α locus are targets of the VHL E3 ubiquitin ligase complex. J. Bio. Chem., 278: 11032-11040.
  21. Lando, D., D.J. Peet, D.A. Whelan, J.J. Gorman and M.L. Whitelaw, 2002. Asparagine hydroxylation of the HIF transactivation domain a hypoxic switch. Science, 295: 858-861.
  22. Lando, D., D.J. Peet, J.J. Gorman, D.A. Whelan, M.L. Whitelaw and R.K. Bruick, 2002. FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of Hypoxia Inducible Factor. Genes Dev., 16: 1466-1471.

Search

Leave a Comment

Your email address will not be published. Required fields are marked *